Research programme: human papillomavirus therapeutics - Celldex Therapeutics Inc
Alternative Names: CDX-2410Latest Information Update: 26 Sep 2008
At a glance
- Originator Celldex Therapeutics Inc
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Human papillomavirus infections
Most Recent Events
- 23 Feb 2007 Preclinical trials in Human papillomavirus infections in USA (unspecified route)